Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

2020 ◽  
Vol 131 ◽  
pp. 27-36 ◽  
Author(s):  
Alexis B. Cortot ◽  
Clarisse Audigier-Valette ◽  
Olivier Molinier ◽  
Sylvestre Le Moulec ◽  
Fabrice Barlesi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Weekly Paclitaxel ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
Third Line Treatment

Second and third line treatment in non-small cell lung cancer

2009 ◽  
Vol 71 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Adolfo Favaretto ◽  
Giulia Pasello ◽  
Cristina Magro ◽  
Clorinda Schettino ◽  
Cesare Gridelli
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
Third Line Treatment

scholarly journals Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer

2021 ◽  
pp. 1-1
Author(s):  
Caitlin Smare ◽  
Kiran Dave ◽  
Ariadna Juarez-Garcia ◽  
Pranav Abraham ◽  
John R. Penrod ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

Second- and Third-line Treatment in Advanced Non-small-cell Lung Cancer

2009 ◽  
Vol 05 (01) ◽  
pp. 38
Author(s):  
Adolfo Favaretto ◽  
Giulia Pasello ◽  
◽  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cytotoxic Agents ◽  
Third Generation ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
Third Line Treatment

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. About 50% of patients present with locally advanced or metastatic disease. First-line therapy usually consists of a combination of cisplatin or carboplatin with a third-generation agent (paclitaxel, docetaxel, gemcitabine or vinorelbine) that results in less than 5% five-year survival. In recent years advances in second- and third-line treatment have led to a prognostic improvement. Two cytotoxic agents, docetaxel and pemetrexed, are approved in NSCLC second-line treatment, and a new class of drugs against specific molecular targets – tyrosine kinase inhibitors – has emerged as an alternative to conventional treatment. Many trials are ongoing to assess the activity of new drugs, alone or in association, or new combinations of third-generation chemotherapeutic agents.

Sign in / Sign up

Export Citation Format

Share Document